(EMAILWIRE.COM, November 29, 2018 ) Browse 91 market data tables and 30 figures spread through 148 pages and in-depth TOC on "Human Microbiome Market"
https://www.marketsandmarkets.com/Market-Reports/human-microbiome-market-37621904.html
Early buyers will receive 10% customization on this report.

The human microbiome market is expected to reach USD 899.1 Million by 2025 from USD 506.5 Million in 2022 growing at a CAGR of 21.1% during the forecast period (2022–2025).

Enterome Bioscience (France), Yakult (Japan), DuPont (U.S.), Metabiomics Corporation (U.S.), ViThera Pharmaceuticals (U.S.), Second Genome Inc. (U.S.), MicroBiome Therapeutics LLC (U.S.), Vedanta BioSciences (U.S.), Osel, Inc. (U.S.), and Merck (U.S.) are the major players in the human microbiome market. Domination of the individual segments in this market will depend on the core competencies of different players.

Companies that launch products targeted at specific indications in the human microbiome market are likely to maintain their positions in this market. Pfizer is one such company; it releases medicines and vaccines for specific indications. The firm also entered into an agreement with Second Genome for microbiome research in obesity and metabolic disorders.

Download the PDF Brochure@ http://bit.ly/2RkpzeD

Companies in the human microbiome market are majorly focusing on expanding and entering segments for new indications and technology. The key strategy is to expand market share through acquisitions and connect financially with firms having common values and goals. To gain maximum market share, companies have been aggressively signing agreements, collaborations, and partnerships with third-party vendors.

Enterome Bioscience is one such company the company focuses on developing biomarkers, companion diagnostic kits, and therapeutic solutions. The company provides products and technologies in the emerging areas of disease management for human gut microbiome and drugs for the treatment of various microbiome-related diseases, such as inflammatory bowel disease, metabolic diseases, and related disorders.

In-depth research into the human microbiome market revealed that agreements, partnerships, and collaborations were the key strategies adopted by major players to enter the microbiome business or expand their microbiome business units.

Major players that adopted this strategy include Second Genome (U.S.), Enterome Bioscience (France), Vedanta Bioscience (U.S.), and Osel, Inc. (U.S.). In April 2016, Enterome entered an agreement with Vertex Pharmaceuticals Inc. (U.S.) to research, develop, and commercialize novel small molecule FimH antagonists, to be utilized in the treatment of inflammatory bowel diseases (IBD).

Get the Sample Pages for More Details@ http://bit.ly/2BCHYOc

Companies in the Asia-Pacific regions are also entering the field of microbiome. Yakult Honsha Co., Ltd. is one such company which is engaged in manufacturing and marketing food and beverage products. The company operates through three business segments, namely, Food and Beverages, Pharmaceuticals, and Others. The Food and Beverages segment includes juices, soft drinks, and healthy foods. This segment also includes probiotic drinks that contain Lactobacillus casei, a bacterium which improves intestinal function and immunity.

About MarketsandMarkets™

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets’s flagship competitive intelligence and market research platform, "Knowledgestore" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Contact:
Mr. Shelly Singh
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
sales@marketsandmarkets.com